First-to-invent versus first-to-file: impact of the AIA

Tara Rachinsky; Clark Sullivan; Shubha Ghosh; David S. Resnick; Carlyn Burton; Mary Anne Armstrong; John P. Hanish; Alexandra Sklan

doi:10.4155/ppa.14.28

First-to-invent versus first-to-file: impact of the AIA

Tara Rachinsky, Clark Sullivan, Shubha Ghosh, David S. Resnick, Carlyn Burton, Mary Anne Armstrong, John P. Hanish, Alexandra Sklan

Research output: Contribution to journal › Article › peer-review

Abstract

On March 16, 2013, the USPTO switched from a 'first-to-invent' to a 'first-to-file' patent system. Under the 2011 America Invents Act, patents will be awarded to the first inventor to file a patent application as opposed to the date of invention. Now, over a year since the main provisions of the America Invents Act (AIA) came into effect, Pharmaceutical Patent Analyst has invited a selection of IP specialists and researchers from the US to discuss the implications of this new law and how it will affect future pharmaceutical and medical R&D. Interview conducted by Alexandra Sklan, Commissioning Editor.

Original language	English (US)
Pages (from-to)	353-359
Number of pages	7
Journal	Pharmaceutical patent analyst
Volume	3
Issue number	4
DOIs	https://doi.org/10.4155/ppa.14.28
State	Published - Jul 1 2014
Externally published	Yes

ASJC Scopus subject areas

General Medicine

Access to Document

10.4155/ppa.14.28

Cite this

@article{c6c06d518522467283a6bd222e7b5287,

title = "First-to-invent versus first-to-file: impact of the AIA",

abstract = "On March 16, 2013, the USPTO switched from a 'first-to-invent' to a 'first-to-file' patent system. Under the 2011 America Invents Act, patents will be awarded to the first inventor to file a patent application as opposed to the date of invention. Now, over a year since the main provisions of the America Invents Act (AIA) came into effect, Pharmaceutical Patent Analyst has invited a selection of IP specialists and researchers from the US to discuss the implications of this new law and how it will affect future pharmaceutical and medical R&D. Interview conducted by Alexandra Sklan, Commissioning Editor. ",

author = "Tara Rachinsky and Clark Sullivan and Shubha Ghosh and Resnick, {David S.} and Carlyn Burton and Armstrong, {Mary Anne} and Hanish, {John P.} and Alexandra Sklan",

year = "2014",

month = jul,

day = "1",

doi = "10.4155/ppa.14.28",

language = "English (US)",

volume = "3",

pages = "353--359",

journal = "Pharmaceutical patent analyst",

issn = "2046-8954",

publisher = "Future Science",

number = "4",

}

TY - JOUR

T1 - First-to-invent versus first-to-file

T2 - impact of the AIA

AU - Rachinsky, Tara

AU - Sullivan, Clark

AU - Ghosh, Shubha

AU - Resnick, David S.

AU - Burton, Carlyn

AU - Armstrong, Mary Anne

AU - Hanish, John P.

AU - Sklan, Alexandra

PY - 2014/7/1

Y1 - 2014/7/1

N2 - On March 16, 2013, the USPTO switched from a 'first-to-invent' to a 'first-to-file' patent system. Under the 2011 America Invents Act, patents will be awarded to the first inventor to file a patent application as opposed to the date of invention. Now, over a year since the main provisions of the America Invents Act (AIA) came into effect, Pharmaceutical Patent Analyst has invited a selection of IP specialists and researchers from the US to discuss the implications of this new law and how it will affect future pharmaceutical and medical R&D. Interview conducted by Alexandra Sklan, Commissioning Editor.

AB - On March 16, 2013, the USPTO switched from a 'first-to-invent' to a 'first-to-file' patent system. Under the 2011 America Invents Act, patents will be awarded to the first inventor to file a patent application as opposed to the date of invention. Now, over a year since the main provisions of the America Invents Act (AIA) came into effect, Pharmaceutical Patent Analyst has invited a selection of IP specialists and researchers from the US to discuss the implications of this new law and how it will affect future pharmaceutical and medical R&D. Interview conducted by Alexandra Sklan, Commissioning Editor.

UR - http://www.scopus.com/inward/record.url?scp=84958698101&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84958698101&partnerID=8YFLogxK

U2 - 10.4155/ppa.14.28

DO - 10.4155/ppa.14.28

M3 - Article

C2 - 25291309

AN - SCOPUS:84958698101

SN - 2046-8954

VL - 3

SP - 353

EP - 359

JO - Pharmaceutical patent analyst

JF - Pharmaceutical patent analyst

IS - 4

ER -

First-to-invent versus first-to-file: impact of the AIA

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this